Call us toll free: +39 075 80.12.764
Top notch Multipurpose WordPress Theme!




After the lifting of the lockdown imposed to curb the spread of Covid-19, S&R Farmaceutici S.p.A. has resumed all activities, including the presence of pharmaceutical representatives all over the country. Meetings have also resumed, in particular, the meeting of the 3rd cycle took place at the Cenacolo Hotel in Assisi, over three days, from Monday 7th to Wednesday 9th September, rich in food for thought and topics.

During the plenary session, opened by the Chief Executive Officer Mauro Dionigi, the General Manager Luca Leonardi illustrated the scenario for the future of S&R Farmaceutici, characterised by positive upward trends, along with estimates for the end of 2020.

Dionigi reported that “8% growth was recorded during the first half of 2020, which by the end of the year will be 22% higher than the previous year. The pharmaceutical sector continues to give positive signals, therefore the goal we set ourselves, to end the year with 30 million euros in turnover, will be achieved and may even be exceeded”.

During these three days, researchers and specialised doctors had the chance to broaden their knowledge of different S&R Farmaceutici products, from the company’s urology and gynaecology line. ‘Genante’ stands out in particular, a nutraceutical product which contains resveratrol and is an immense source of satisfaction for our company, even receiving the Best biotechnology product award 2019 at the ‘European biotechnology congress’ in Valencia and the focus of a study published in an important international journal.

Leonardi described how “The best news we received during the lockdown came from Fertility & Sterility, an important international scientific journal, practically the ‘Bible’ of fertility, which published a scientific study on our product, a source of immense fulfilment for all the work that went into its creation”.

About the Author:

Sorry, the comment form is closed at this time.